MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
Insulet Corporation Operating Income 2011-2026 | PODD
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Insulet Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 474 M | 309 M | 220 M | 37.6 M | 126 M | 51.5 M | 50 M | 27.4 M | -7.4 M | -10.7 M | -48.7 M | -8.87 M | -26.7 M | -36 M | -42.5 M | -38.6 M | -59.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 474 M | -59.4 M | 59.8 M |
Quarterly Operating Income Insulet Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122 M | 118 M | 121 M | 88.8 M | - | 88.1 M | 54.5 M | 56.9 M | - | 54.8 M | 31.1 M | 27.7 M | - | 2.9 M | -26.7 M | 37.9 M | - | 33.7 M | 26.3 M | 16.3 M | - | 23.8 M | 27.5 M | 7.5 M | - | 17 M | 7.6 M | 7.3 M | 16.2 M | 6.86 M | 4.32 M | - | -768 K | 2.05 M | -3.36 M | -5.31 M | -4.14 M | 2.42 M | -1.29 M | -7.7 M | -12.6 M | -14.8 M | -14.1 M | -7.27 M | - | -2.88 M | -5.28 M | -1.89 M | - | -17.3 M | -5.82 M | -6.21 M | - | -8.47 M | -10.5 M | -10.9 M | - | -9.77 M | -14.9 M | -7.27 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 122 M | -26.7 M | 16.4 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.3 | -0.69 % | $ 161 M |  France |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K |  USA |
 |
Axonics Modulation Technologies
AXNX
|
-26.1 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Helius Medical Technologies
HSDT
|
-244 M | $ 2.29 | -2.97 % | $ 50.5 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 11.44 | -2.22 % | $ 324 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.01 | - | $ 17.1 M | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 8.27 | 0.49 % | $ 1.24 B | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 73.83 | 0.26 % | $ 4.03 B |  Britain |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.55 | 0.65 % | $ 63.1 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.46 | 0.17 % | $ 28.6 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 18.37 | -0.33 % | $ 431 M | USA |
 |
MiMedx Group
MDXG
|
63.9 M | $ 3.62 | 0.28 % | $ 535 M | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 11.02 | -3.76 % | $ 395 M | USA |
 |
Myomo
MYO
|
-14.4 M | $ 1.04 | 9.47 % | $ 43.5 M | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 6.09 | 2.35 % | $ 72.8 M | USA |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 10.75 | 3.27 % | $ 426 M |  Curacao |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Profound Medical Corp.
PROF
|
-41.3 M | $ 6.83 | -2.01 % | $ 206 M | Canada |
 |
Electromed
ELMD
|
9.66 M | $ 38.22 | -0.93 % | $ 323 M | USA |
 |
Butterfly Network
BFLY
|
-86.4 M | $ 4.47 | -0.22 % | $ 1.1 B | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 84.81 | 0.24 % | $ 11.5 B | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.39 | 3.91 % | $ 6.63 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 37.23 | 0.57 % | $ 1.16 B | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 43.84 | -2.01 % | $ 1.29 B | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 89.28 | -0.8 % | $ 3.1 B | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 85.78 | 3.1 % | $ 50.2 B | USA |
 |
TransMedics Group
TMDX
|
109 M | $ 68.94 | 0.12 % | $ 2.34 B | USA |